<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02928614</url>
  </required_header>
  <id_info>
    <org_study_id>137.08</org_study_id>
    <nct_id>NCT02928614</nct_id>
  </id_info>
  <brief_title>Biomarkers in Obese Patients With Knee Osteoarthritis; Weight Maintenance</brief_title>
  <acronym>BIO-LOSEIT-II</acronym>
  <official_title>Biomarkers in Obese Patients With Knee Osteoarthritis Following Long-term Weight Maintenance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henrik Gudbergsen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Parker Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a substudy to a randomized trial investigating the effect of liraglutide on body
      weight and pain in overweight or obese patients with knee osteoarthritis (NCT02905864). In
      the parent trial, patients will be subjected to an 8-week diet intervention phase including a
      low-calorie diet and dietetic counseling, after which they will be randomized to receive
      either liraglutide 3 mg or liraglutide 3 mg placebo as an add-on to dietetic guidance on
      re-introducing regular foods and a focus on continued motivation to engage in a healthy
      lifestyle.

      This substudy aims to investigate the impact of, and subsequent change of biomarkers in obese
      patients with knee osteoarthritis following a randomization to Liraglutide 3 mg or
      Liraglutide 3 mg placebo treatment between weeks 0-52.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in collagen II degradation fragment α-C2M</measure>
    <time_frame>Week 0 to 52</time_frame>
    <description>Blood sampling</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in collagen II degradation fragment β-C2M</measure>
    <time_frame>Week 0 to 52</time_frame>
    <description>Blood sampling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in non-coding RNA type snoRNAs U38 and U48</measure>
    <time_frame>Week 0 to 52</time_frame>
    <description>Blood sampling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in miRNA-454</measure>
    <time_frame>Week 0 to 52</time_frame>
    <description>Blood sampling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in miRNA let-7e</measure>
    <time_frame>Week 0 to 52</time_frame>
    <description>Blood sampling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Nesfatin-1</measure>
    <time_frame>Week 0 to 52</time_frame>
    <description>Blood sampling</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Osteoarthritis</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Liraglutide 3 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm description: Subjects will be up titrated to liraglutide 3 mg QD and stay on that dose for the remainder of the 52-week drug intervention period.
Drug: Liraglutide 3 mg QD administered in a 6 mg/mL, 3 mL pen for subcutaneous injection.
Dose escalation scheme: Initial dosage of 0.6 mg per day, escalated bi-weekly by 0.6 mg to 3 mg per day over a total of 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Liraglutide 3 mg placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Arm description: Subjects will be up titrated to liraglutide 3 mg placebo QD and stay on that dose for the remainder of the 52-week drug intervention period.
Drug: Liraglutide 3 mg placebo QD administered in a 6 mg/mL drug equivalent volumes, 3 mL pen for subcutaneous injection.
Dose escalation scheme: Initial dosage of a 0.6 mg drug equivalent volume per day, escalated bi-weekly by an 0.6 mg drug equivalent volume per day to a 3 mg drug equivalent volume per day over a total of 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liraglutide 3 mg (Saxenda)</intervention_name>
    <arm_group_label>Liraglutide 3 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liraglutide 3 mg placebo</intervention_name>
    <arm_group_label>Liraglutide 3 mg placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Same as parent trial (NCT02905864)

        Exclusion Criteria:

          -  Same as parent trial (NCT02905864)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Parker Institute</name>
      <address>
        <city>Frederiksberg</city>
        <state>Capital Region</state>
        <zip>2000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lars Erik Kristensen, MD, PhD</last_name>
      <phone>+45 38 16 41 55</phone>
      <email>lars.erik.kristensen@regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>henrik r gudbergsen, MD, PhD</last_name>
      <phone>+45 29 84 28 88</phone>
      <email>henrik.rindel.gudbergsen.01@regionh.dk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 7, 2016</study_first_submitted>
  <study_first_submitted_qc>October 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2016</study_first_posted>
  <last_update_submitted>November 11, 2016</last_update_submitted>
  <last_update_submitted_qc>November 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Parker Research Institute</investigator_affiliation>
    <investigator_full_name>Henrik Gudbergsen</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Osteoarthritis</keyword>
  <keyword>Obesity</keyword>
  <keyword>Liraglutide 3 mg</keyword>
  <keyword>Liraglutide</keyword>
  <keyword>Biomarkers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

